Your browser doesn't support javascript.
loading
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.
Gaig, Carles; Compta, Yaroslau; Heidbreder, Anna; Marti, Maria J; Titulaer, Maarten J; Crijnen, Yvette; Högl, Birgit; Lewerenz, Jan; Erro, María Elena; Garcia-Monco, Juan Carlos; Nigro, Pasquale; Tambasco, Nicola; Patalong-Ogiewa, Maja; Erdler, Marcus; Macher, Stefan; Berger-Sieczkowski, Evelyn; Höftberger, Romana; Geis, Christian; Hutterer, Markus; Milán-Tomás, Angela; Martin-Bastida, Antonio; Manzanares, Lydia Lopez; Quintas, Sonia; Höglinger, Günter U; Möhn, Nora; Schoeberl, Florian; Thaler, Franziska S; Asioli, Gian Maria; Provini, Federica; Plazzi, Giuseppe; Berganzo, Koldo; Blaabjerg, Morten; Brüggemann, Norbert; Farias, Tarsis; Ng, Chen Fei; Giordana, Caroline; Herrero-San Martín, Alejandro; Huebra, Lucio; Kotschet, Katya; Liendl, Herburg; Montojo, Teresa; Morata, Carlos; Perez, Jesus Perez; Puertas, Inmaculada; Seifert-Held, Thomas; Seitz, Caspar; Simabukuro, Mateus Mistieri; Tellez, Nieves; Villacieros-Álvarez, Javier; Willekens, Barbara.
Afiliação
  • Gaig C; Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Compta Y; Department of Neurology, Hospital Clinic, Barcelona, Spain.
  • Heidbreder A; Multidisciplinary Sleep Disorders Unit, Hospital Clinic, Barcelona, Spain.
  • Marti MJ; Department of Neurology, Hospital Clinic, Barcelona, Spain.
  • Titulaer MJ; Parkinson's disease & Movement Disorders Unit, Hospital Clinic, Barcelona, Spain.
  • Crijnen Y; Department Neurology, Division of Sleep Medicine and Neuromuscular Disorders, University Hospital Muenster, Muenster, Germany.
  • Högl B; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Lewerenz J; Department of Neurology, Hospital Clinic, Barcelona, Spain.
  • Erro ME; Parkinson's disease & Movement Disorders Unit, Hospital Clinic, Barcelona, Spain.
  • Garcia-Monco JC; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Nigro P; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Tambasco N; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Patalong-Ogiewa M; Department of Neurology, Ulm University, Ulm, Germany.
  • Erdler M; Neurology Department, Complejo Hospitalario de Navarra, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Macher S; Neurology Department. Hospital Universitario de Basurto. Bilbao. Spain (formerly Department of Neurology, Hospital de Galdakao, Spain).
  • Berger-Sieczkowski E; Movement Disorders Center, Perugia General Hospital and University of Perugia, Perugia, Italy.
  • Höftberger R; Movement Disorders Center, Perugia General Hospital and University of Perugia, Perugia, Italy.
  • Geis C; Department of Neurology and Neurorehabilitation. Faculty of Medical Sciences in Katowice. Medical University of Silesia, Katowice, Poland.
  • Hutterer M; Department of Neurology, Klinik Donaustadt, Karl-Landsteiner-Institut, Vienna, Austria.
  • Milán-Tomás A; Department of Neurology, Medical University of Vienna, Austria.
  • Martin-Bastida A; Department of Neurology, Medical University of Vienna, Austria.
  • Manzanares LL; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Austria.
  • Quintas S; Section Translational Neuroimmunology, Department of Neurology, Jena University Hospital, Jena, Germany.
  • Höglinger GU; Department of Neurology 1, Neuromed Campus, Kepler Universitätsklinikum Linz, Linz, Austria. Department of Neurology with Stroke Unit and Acute Geriatrics, Saint John of God Hospital Linz, Linz, Austria.
  • Möhn N; Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona-Madrid. Spain.
  • Schoeberl F; Department of Neurology and Neurosciences, Clínica Universidad de Navarra, Pamplona-Madrid. Spain.
  • Thaler FS; Department of Neurology, Hospital La Princesa, Madrid, Spain.
  • Asioli GM; Department of Neurology, Hospital La Princesa, Madrid, Spain.
  • Provini F; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Plazzi G; Department of Neurology, Hannover Medical School, Hannover, Germany.
  • Berganzo K; Department of Neurology, Ludwig-Maximilians-University; Munich, Germany.
  • Blaabjerg M; Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.
  • Brüggemann N; Department of Biomedical and NeuroMotor Sciences (DiBiNeM), Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Farias T; Department of Biomedical and NeuroMotor Sciences (DiBiNeM), Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Ng CF; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Giordana C; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy.
  • Herrero-San Martín A; Neurology Department, Cruces University Hospital, Barakaldo, Spain.
  • Huebra L; Department of Neurology, Odense University Hospital, Odense, Denmark.
  • Kotschet K; Department of Neurology and Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
  • Liendl H; Department of Neurology, Medical Clinic of Hospital Geral Cleriston Andrade, Feira de Santana, Brazil.
  • Montojo T; Neurology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
  • Morata C; Department of Movement Disorders and Neurology, CHU Nice, Nice, France.
  • Perez JP; Department of Neurology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Puertas I; Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Seifert-Held T; Clinical Neurosciences, St Vincent's Hospital, Melbourne, Australia.
  • Seitz C; Department of Neurology, LKH Murtal, Standort Knittelfeld, Austria.
  • Simabukuro MM; Department of Neurology, Fundación Jiménez Diaz, Madrid, Spain.
  • Tellez N; Department of Neurology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Villacieros-Álvarez J; Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Willekens B; Department of Neurology, Hospital La Paz, Madrid, Spain.
Neurology ; 2021 Aug 11.
Article em En | MEDLINE | ID: mdl-34380749
ABSTRACT

OBJECTIVE:

Anti-IgLON5 disease is a recently described neurological disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are under-reported. Here we describe the frequency and types of movement disorders in a series of consecutive patients with this disease.

METHODS:

In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by three experts in movement disorders.

RESULTS:

Seventy two patients were included. In 41 (57%) the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least one movement disorder with a median of three per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients, 72%), chorea (24, 33%), bradykinesia (20, 28%), dystonia (19, 26%), abnormal body postures or rigidity (18, 25%), and tremor (15, 21%). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients, 32%) including dystonia (13), myorhythmia (6), chorea (4) or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31(43%) of patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only seven (13%) cases.

CONCLUSIONS:

Movement disorders are a frequent and leading cause of initial neurological consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Qualitative_research Idioma: En Revista: Neurology Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Qualitative_research Idioma: En Revista: Neurology Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha País de publicação: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA